is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of biosimilars, APIs, and
Oral GLP-1s slow gastric emptying to reduce appetite and control blood sugar, but this delay in digestion can trigger symptoms like nausea, bloating, reflux, constipation, and gas, especially in people with sensitive digestive systems
FDA approval timeline June 2023 : Phase 2 results in the New England Journal of Medicine 17.5% weight loss at 24 weeks December 2025 : TRIUMPH-4 results 28.7% weight loss March 2026 : TRANSCEND-T2D-1 results glycemic control + weight loss May 2026 : TRIUMPH-1 results up to 28.3% / 70 lbs over 80 weeks Late 2026 (est.) : Remaining TRIUMPH trials complete
Stopping the medication abruptly can have adverse effects on your health, especially if you are using it for diabetes management or weight loss.